News

Her Two Wheels on MSN15d
Watch before you buy Motorcycle Camping gear! Best and WORST gear I own!
In this video, we explore the best and worst gear for motorcycle camping, including: **Tent:** - Best - Worst **Cookware:** - Best - Worst **Pillow:** - Best - Worst **Sleeping Bag:** - Best - Worst * ...
Yahoo Finance5d
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting
WALTHAM, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically ...
Benzinga.com5d
Why Is Dyne Therapeutics Stock Trading Lower On Tuesday?
DYNE-101 improved myotonia by 3.3 seconds at 6 months; gains sustained through 12 months across multiple measures. Accelerated approval filing shifted to late 2026; Phase 3 trial expected to start ...
Seeking Alpha4d
Dyne Therapeutics: Emergence As A Superior DM1/DMD Player Warrants Rating Upgrade
Upgrading Dyne Therapeutics to 'Buy' due to promising late-stage DM1 and DMD drug candidates and significant unmet need in both indications. Recent management changes and a more measured clinical ...
Investing4d
H.C. Wainwright reiterates buy rating on Dyne Therapeutics stock
H.C. Wainwright reiterated its Buy rating and $38.00 price target on Dyne Therapeutics (NASDAQ:DYN) Wednesday following the company’s regulatory and trial updates for its DYNE-101 program.
Investing5d
Dyne’s DM1 treatment receives FDA breakthrough designation
WALTHAM, Mass. - Dyne Therapeutics, Inc. (NASDAQ:DYN), a $1.57 billion market cap biotech company currently trading at $13.82, announced Tuesday that the U.S. Food and Drug Administration has ...
Nasdaq5d
Dyne Therapeutics Submits Revised ACHIEVE Trial Protocol Elevating vHOT as Primary Endpoint for U.S. Accelerated Approval of DYNE-101 in Myotonic Dystrophy Type 1
Dyne Therapeutics has announced a revised protocol for its ACHIEVE trial, elevating video hand opening time (vHOT) to the primary endpoint for U.S. Accelerated Approval of DYNE-101, a treatment ...
Morningstar6d
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting
Based on Type C meeting and new data, Dyne submitted revised ACHIEVE trial protocol to FDA elevating vHOT to primary endpoint for U.S. Accelerated Approval - - New positive clinical data from ...
manilatimes6d
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting
Based on Type C meeting and new data, Dyne submitted revised ACHIEVE trial protocol to FDA elevating vHOT to primary endpoint for U.S. Accelerated Approval - - New positive clinical data from Phase ...
The New York Times3d
NHL Draft risers and fallers, ranking top prospects, trading picks, more: Mailbag
Today, I answered some of your questions as the 2025 NHL Draft is quickly approaching. Note: Submitted questions may be edited for clarity and style. Which top center prospects for this draft are ...
Investing5d
Dyne’s DM1 treatment receives FDA breakthrough designation
WALTHAM, Mass. - Dyne Therapeutics, Inc. (NASDAQ:DYN), a $1.57 billion market cap biotech company currently trading at $13.82, announced Tuesday that the U.S. Food and Drug Administration has granted ...